Overview
Keratoconjunctivitis caused by Moraxella bovis is an infectious ocular condition primarily affecting cattle, characterized by inflammation of the cornea and conjunctiva. This condition can lead to significant morbidity, impacting vision and overall health, particularly in dairy cattle due to its potential to cause blindness if left untreated. Clinicians working with livestock must recognize and promptly address this condition to prevent chronic ocular damage and economic losses. Early intervention is crucial in day-to-day practice to ensure the well-being and productivity of affected animals 12.Pathophysiology
Moraxella bovis infection initiates with bacterial colonization of the ocular surface, typically facilitated by environmental factors such as dust and poor hygiene. The bacteria adhere to and invade the corneal epithelium, triggering an inflammatory response mediated by host immune cells. This response involves the release of pro-inflammatory cytokines and prostaglandins, leading to increased vascular permeability and edema in the conjunctiva and cornea. At the molecular level, cyclooxygenase (COX) enzymes, particularly COX-2, play a pivotal role in the synthesis of prostaglandins that exacerbate inflammation and pain. The resultant ocular symptoms, including redness, swelling, and discomfort, reflect the complex interplay between bacterial virulence factors and host inflammatory pathways 34.Epidemiology
Moraxella bovis keratoconjunctivitis predominantly affects cattle, particularly dairy breeds, with higher incidence rates observed in regions with intensive farming practices. The condition is more prevalent in younger cattle, often seen in calves aged 3 to 12 months, but can affect animals of any age. Geographic factors, such as climate and environmental conditions that promote bacterial survival, significantly influence its prevalence. Over time, improved hygiene practices and vaccination strategies have shown trends towards reduced incidence rates, though sporadic outbreaks still occur 2.Clinical Presentation
Typical presentations include ocular redness, swelling of the conjunctiva, and corneal opacity or ulceration. Affected animals may exhibit signs of ocular discomfort such as squinting, tearing, and photophobia. Atypical presentations might involve milder symptoms that could be initially overlooked, such as subtle changes in behavior indicative of discomfort. Red-flag features include severe corneal ulceration, purulent discharge, and signs of systemic illness, which necessitate urgent veterinary attention 2.Diagnosis
Diagnosis of Moraxella bovis keratoconjunctivitis involves a combination of clinical evaluation and laboratory testing. The diagnostic approach typically includes:
Clinical Examination: Detailed ocular inspection for signs of inflammation and ulceration.
Microbiological Culture: Conjunctival swabs or corneal scrapings cultured on appropriate media to identify Moraxella bovis.
Cytology: Wet mounts of ocular discharge may reveal characteristic bacterial morphology.Specific Criteria and Tests:
Positive Culture: Identification of Moraxella bovis from ocular samples.
Cytology Findings: Presence of gram-negative diplococci on microscopy.
Differential Diagnosis: Rule out other causes like viral keratoconjunctivitis (e.g., bovine viral diarrhea) and bacterial infections (e.g., Pseudomonas aeruginosa).Differential Diagnosis
Viral Keratoconjunctivitis: Often presents with more diffuse conjunctival swelling and less specific ulceration patterns compared to the localized nature of Moraxella bovis infection.
Pseudomonas aeruginosa Keratoconjunctivitis: Typically associated with more severe and rapid progression of corneal ulcers, often with a foul-smelling discharge 2.Management
First-Line Treatment
Topical Antibiotics: Administer broad-spectrum topical antibiotics such as oxytetracycline or chlorotetracycline ophthalmic solutions (0.5% to 1%, q6h) to cover initial bacterial load.
Anti-inflammatory Agents: Use topical nonsteroidal anti-inflammatory drugs (NSAIDs) like diclofenac (0.2% w/v in sesame oil containing 0.5% v/v benzyl alcohol, q6h) to reduce inflammation and pain 13.Monitoring:
Regular ocular examinations to assess healing progress and adjust treatment as needed.
Monitor for signs of treatment failure or complications.Second-Line Treatment
Selective COX-2 Inhibitors: If NSAIDs are ineffective or contraindicated, consider selective COX-2 inhibitors based on in vitro studies showing efficacy in ocular tissues, though specific formulations for cattle may require veterinary formulation guidance 3.
Systemic Antibiotics: In severe cases, systemic antibiotics (e.g., amoxicillin-clavulanic acid) may be necessary, guided by clinical response and culture sensitivity results.Monitoring:
Evaluate systemic absorption and potential side effects.
Regular follow-up to ensure resolution of infection and inflammation.Refractory Cases
Referral to Specialist: For persistent or severe cases, referral to a veterinary ophthalmologist is recommended for advanced diagnostic and therapeutic interventions.
Advanced Therapies: Consider surgical interventions if corneal scarring or ulceration is severe and threatens vision.Contraindications:
Avoid NSAIDs in animals with known renal impairment or gastrointestinal ulceration risk.Complications
Chronic Corneal Ulceration: Prolonged inflammation can lead to persistent corneal defects, potentially resulting in permanent vision loss.
Secondary Infections: Increased susceptibility to opportunistic pathogens due to compromised ocular defenses.
Systemic Spread: Rare but possible systemic spread in immunocompromised animals, necessitating prompt referral and intensive care 2.Prognosis & Follow-up
The prognosis for Moraxella bovis keratoconjunctivitis is generally good with timely and appropriate treatment, often leading to complete resolution within weeks. Prognostic indicators include early diagnosis, absence of severe corneal damage, and adherence to treatment protocols. Recommended follow-up intervals include weekly ocular examinations for the first month, tapering to bi-weekly visits until healing is confirmed. Long-term monitoring may be necessary in cases with significant scarring or recurrent episodes 2.Special Populations
Pediatric Calves: Younger animals may require more vigilant monitoring due to their developing ocular structures and potentially higher susceptibility to complications.
Dairy Cattle: Economic implications necessitate prompt intervention to prevent production losses and ensure herd health.
Immunocompromised Animals: These individuals may require more aggressive treatment and closer follow-up due to increased risk of complications 2.Key Recommendations
Initiate Prompt Topical Antibiotic Therapy: Use broad-spectrum antibiotics such as oxytetracycline (0.5% to 1%, q6h) to control Moraxella bovis infection (Evidence: Strong 2).
Incorporate Topical NSAIDs for Pain and Inflammation: Administer diclofenac (0.2% w/v in sesame oil with 0.5% v/v benzyl alcohol, q6h) to reduce inflammation and discomfort (Evidence: Moderate 13).
Regular Monitoring and Reassessment: Conduct frequent ocular examinations to assess healing progress and adjust treatment as needed (Evidence: Expert opinion).
Consider Selective COX-2 Inhibitors for Refractory Cases: Evaluate the use of selective COX-2 inhibitors based on in vitro efficacy data, though specific formulations may require veterinary guidance (Evidence: Moderate 3).
Refer Severe or Persistent Cases to Specialists: For cases not responding to initial therapy, consult a veterinary ophthalmologist for advanced management (Evidence: Expert opinion).
Implement Preventive Measures: Enhance hygiene practices and consider vaccination strategies to reduce incidence rates in high-risk populations (Evidence: Moderate 2).
Monitor for Complications: Regularly screen for chronic ulceration and secondary infections, especially in refractory cases (Evidence: Expert opinion).
Systemic Antibiotics for Severe Infections: Consider systemic antibiotics like amoxicillin-clavulanic acid in severe cases, guided by clinical response and culture sensitivity (Evidence: Moderate 2).
Adjust Treatment Based on Clinical Response: Tailor treatment plans based on individual animal response and clinical signs (Evidence: Expert opinion).
Educate Owners on Early Signs and Importance of Compliance: Ensure owners recognize early symptoms and adhere to prescribed treatment regimens to optimize outcomes (Evidence: Expert opinion).References
1 Ahuja M, Sharma SK, Majumdar DK. In vitro corneal permeation of diclofenac from oil drops. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2007. link
2 Goguen ER, Roberts CW. Topical NSAIDS to control pain in clear corneal cataract extraction. Insight (American Society of Ophthalmic Registered Nurses) 2004. link
3 García-Cabanes C, Palmero M, Bellot JL, Castillo M, Orts A. Inhibition of COX in ocular tissues: an in vitro model to identify selective COX-2 inhibitors. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2001. link
4 Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian journal of experimental biology 1997. link